Royal College of Surgeons in Ireland
Browse

Assessing mode of recurrence in breast cancer to identify an optimised follow-up pathway: 10-year institutional review

Download (467.37 kB)
journal contribution
posted on 2024-09-20, 10:12 authored by Jack Horan, Conor Reid, Michael R. Boland, Gordon DalyGordon Daly, Stephen KeelanStephen Keelan, Angus J. Lloyd, Eithne Downey, Adam Walmsley, Marie Staunton, Colm PowerColm Power, Abeeda ButtAbeeda Butt, Deirdre DukeDeirdre Duke, Arnold HillArnold Hill

Background: Breast cancer surveillance programmes ensure early identification of recurrence which maximises overall survival. Programmes include annual clinical examination and radiological assessment. There remains debate around the value of annual clinical exam in diagnosing recurrent disease/second primaries. The aim was to assess diagnostic modalities for recurrent breast cancer with a focus on evaluating the role of annual clinical examination.

Patients and methods: A prospectively maintained database from a symptomatic breast cancer service between 2010-2020 was reviewed. Patients with biopsy-proven recurrence/second breast primary were included. The primary outcome was the diagnostic modality by which recurrences/secondary breast cancers were observed. Diagnostic modalities included (i) self-detection by the patient, (ii) clinical examination by a breast surgeon or (iii) radiological assessment.

Results: A total of 233 patients were identified and, following application of exclusion criteria, a total of 140 patients were included. A total of 65/140 (46%) patients were diagnosed clinically, either by self-detection or clinical examination, while 75/140 (54%) were diagnosed radiologically. A total of 59/65 (91%) of patients clinically diagnosed with recurrence presented to the breast clinic after self-detection of an abnormality. Four (6%) patients had cognitive impairment and recurrence was diagnosed by a carer. Two (3%) patients were diagnosed with recurrence by a breast surgeon at clinical examination. The median time to recurrence in all patients was 48 months (range 2-263 months).

Conclusion: Clinical examination provides little value in diagnosing recurrence (< 5%) and surveillance programmes may benefit from reduced focus on such a modality. Regular radiological assessment and ensuring patients have urgent/easy access to a breast clinic if they develop new symptoms/signs should be the focus of surveillance programmes.

Funding

Open Access funding provided by the IReL Consortium

History

Comments

The original article is available at https://link.springer.com/

Published Citation

Horan J, et al. Assessing mode of recurrence in breast cancer to identify an optimised follow-up pathway: 10-year institutional review. Ann Surg Oncol. 2023;30(10):6117-6124.

Publication Date

21 July 2023

PubMed ID

37479843

Department/Unit

  • Beaumont Hospital
  • Surgery

Research Area

  • Surgical Science and Practice
  • Cancer

Publisher

Springer Science and Business Media LLC

Version

  • Published Version (Version of Record)